Thai Medical Device Regulatory Updates and Timeline 2008-2026

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

This is a dynamic page: regulations are updated continuously, and the current notifications of the Thai FDA and the MoPH prevail. Since the 2019 amendment, Thailand has completed its switch from the old framework to an AMDD-aligned system and has updated the implementing details intensively between 2024 and 2026. This page traces the timeline, identifies the four milestones with the greatest business impact, and lists what is still changing.

1. Key takeaways

Four milestones dominate the business impact ranking. The classification reform of 2019 to 2021 switched the naming from the old three-tier system to Class 1 to 4, requiring every legacy classification conclusion to be redetermined. The unified renewal system of July 2025 fixed the renewal window to October to December each year, with the system automatically closing the import channel on expiry. The new labelling rules effective 20 June 2026 mandate Thai language for home-use devices and a 120-day affixing window, creating revision pressure for small packages and home-use products. And the expansion of the reliance pathway between 2024 and 2026, with HSA and MDA reliance without a holding period, significantly compresses the review time and cost for Class 2 to 4 registrations.

Classification reform. Old three-tier naming replaced by Class 1 to 4; all legacy classification conclusions need redetermination.
Unified renewal. Renewal window fixed to each October to December, with automatic closure of the import channel on expiry.
New labelling rules. Thai language mandatory for home-use devices and a 120-day affixing window.
Reliance expansion. HSA and MDA reliance without a holding period shortens review time and cost for Class 2 to 4.

2. Legal basis

The timeline below lists the principal instruments and their key changes, in chronological order.

2008	Medical Device Act B.E. 2551	The parent law, establishing the device definition (Article 4) and licensing and penalties (Article 116)
2019-12-18 (Royal Gazette)	MoPH risk classification notification B.E. 2562	Establishes the four-tier Class 1 to 4 classification, aligned with the AMDD; disputes decided by the Secretary-General (Article 4)
2019	Medical Device Act (No. 2) B.E. 2562	Introduces the current risk tiers and three registration pathways; amends the reporting duty of Article 41 paragraph 4 and the mandatory recall power of Article 55 paragraph 5
2020	MoPH vigilance notification B.E. 2563	Defect, adverse event and FSCA reporting system: 48 hours, 10 days and 30 days, with semi-annual summaries (replaces the 2016 notification)
2021	Classification reform takes effect	Class 2 to 4 applicable from February 2021; Class 1 listing mandatory from March 2021
2021	MoPH fee notification B.E. 2564	Review fee schedule, replacing the old 2017 schedule (together with the B.E. 2563 fee regulation)
2023	GMP B.E. 2566 and the Good Import and Distribution Practice B.E. 2566	Quality system framework for manufacturers and importers; Class 1 exempt from certification but must conform
2024-06-04	Thai FDA reliance pathway notification (B.E. 2567)	Recognises the United States FDA, European Union notified bodies, Health Canada, the TGA, Japan MHLW (after one year) and WHO PQ (IVD only); HSA and MDA through bilateral reliance without a holding period
2024-09-19 (effective 2024-09-20)	Transfer notification	Unified transfer process for Class 2-4 (Full CSDT plus the consent letter of the original holder plus identity and safety declarations)
2025-01	Class 1 automatic approval	Class 1 devices within the positive list, identified by GMDN code, are approved automatically upon submission
2025-07	Unified renewal system	Renewals of institutional licences and registration certificates handled uniformly in SKYNET, with the window from 1 October to 31 December each year
2025-09-02	Exhibition advertising exemption notification	Device advertising during national or international scientific exhibitions (100 or more participants) and academic conferences exempt from the pre-approval licence (prior notice required)
Signed 2025-11-27 / gazetted 2025-12-22	MoPH labelling notification B.E. 2568	Effective 2026-06-20, replacing B.E. 2563; Thai for home use, Thai or English for professional use; affixing grace period shortened from 180 days to 120 days; old labels usable until 2028-06-20
2026-01	MoPH / Thai FDA notifications	Updated registration requirements for manufacturing establishments; revised record keeping and annual reporting rules (subject to the current notifications)
2026-03 (B.E. 2569)	Thai FDA notifications	Modernised application forms (manufacturing, import, sale) and digital process simplification
Signed 2026-10-06	Reliance pathway expansion	Malaysia MDA joins the Thai reliance plan (alongside Singapore HSA, without a holding period)

Beyond the table, three directions merit watching: the expansion of reliance plan membership, with Malaysia having joined in October 2026 and further additions possible; the digitisation of application forms and processes, through the B.E. 2569 series of notifications of March 2026; and the enforcement interpretation of the labelling rules, through guidance and transitional arrangements following the entry into force of B.E. 2568.

3. Expert insights

The four milestones are best read as a sequence of structural shifts rather than isolated updates. The classification reform of 2019 to 2021 changed the identity of every product in the market, since all legacy documentation carried classification conclusions under the old three-tier naming that required redetermination under Class 1 to 4. The unified renewal system of July 2025 changed the rhythm of portfolio maintenance, because the window is fixed to each October to December and the system automatically closes the import channel on expiry, converting a missed renewal from an administrative nuisance into a supply interruption. The labelling rules effective 20 June 2026 changed the physical product, mandating Thai language for home-use devices and imposing the 120-day affixing window, with revision pressure concentrated on small packages and home-use products. The reliance pathway expansion between 2024 and 2026 changed the economics of entry, since HSA and MDA reliance without a holding period significantly compresses review time and cost for Class 2 to 4 registrations.

4. Practical recommendations

Turn the timeline into an internal regulatory ledger and review it quarterly.
Track four variables in the ledger: the membership list of the reliance pathway; the enforcement interpretation of the labelling notification B.E. 2568 and its 120-day window; the renewal window and fees; and the digitisation adjustments to application forms and processes.
Maintain the ledger in a single place and synchronise it company-wide, so that sales, registration and logistics do not operate on conflicting versions of the facts.
Feed each quarterly review into the affected functions, so classification conclusions, renewal calendars, label artwork plans and reliance strategy are updated in step with the regulatory changes rather than after them.

5. Verification checklist

□ Confirm the Medical Device Act B.E. 2551 (2008) and the Medical Device Act (No. 2) B.E. 2562 (2019).
□ Confirm the MoPH classification notification B.E. 2562 (2019-12-18).
□ Confirm the MoPH vigilance notification B.E. 2563 (2020).
□ Confirm the MoPH GMP notification B.E. 2566 (2023) and the Good Import and Distribution Practice notification B.E. 2566 (2023).
□ Confirm the Thai FDA reliance pathway notification (2024-06-04, B.E. 2567) and the Malaysia MDA accession notification (2026-10-06).
□ Confirm the transfer notification (2024-09-19).
□ Confirm the Class 1 automatic approval notification (2025-01).
□ Confirm the unified renewal system (2025-07).
□ Confirm the exhibition advertising exemption notification (2025-09-02).
□ Confirm the MoPH labelling notification B.E. 2568 (2025, effective 2026-06-20).
□ Confirm the 2026 notifications on manufacturing establishment registration, record keeping and application form updates (B.E. 2569, 2026-03).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.